Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: Expecting Its Application in Temporal Bone Squamous Cell Carcinoma

Abstract

Temporal bone malignant tumors are characterized by atypical clinical symptoms, and easy recurrence and metastasis. They account for 0.2% of head and neck tumors, and the most common pathological type is squamous cell carcinoma. Patients with squamous cell carcinoma of the temporal bone are often at advanced stages when diagnosed, and lose the chance for surgery. Neoadjuvant immunotherapy has recently been approved as the first-line treatment for refractory recurrent/metastatic squamous cell carcinoma of the head and neck. However, it remains to be determined whether neoadjuvant immunotherapy can be used as the first-line treatment for temporal bone squamous cell carcinoma to reduce the tumor stage before surgery, or as a palliative treatment for patients with unresectable advanced stage carcinoma. The present study reviews the development of immunotherapy and its clinical application in head and neck squamous cell carcinoma, summarizes the treatment of temporal bone squamous cell carcinoma, and prospects the neoadjuvant immunotherapy as the first-line treatment for temporal bone squamous cell carcinoma.

Keywords

neoadjuvant immunotherapy / programmed cell death-1 / head and neck squamous cell carcinoma / temporal bone squamous cell carcinoma

References

[1] YokotaT, HommaA, KiyotaN, et al.. Immunotherapy for squamous cell carcinoma of the head and neck. Jpn J Clin Oncol, 2020, 50(10): 1089-1096

[2] GidleyPW, DemonteF. Temporal bone malignancies. Neurosurg Clin N Am, 2013, 24(1): 97-110

[3] Correia-RodriguesP, RamalhoS, MontalvãoP, et al.. External auditory canal carcinoma: clinical characteristics and long-term treatment outcomes. Eur Arch Otorhinolaryngol, 2020, 277(10): 2709-2720

[4] MoskovitzJ, MoyJ, FerrisRL. Immunotherapy for Head and Neck Squamous Cell Carcinoma. Curr Oncol Rep, 2018, 20(2): 22

[5] GavrielatouN, DoumasS, EconomopoulouP, et al.. Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev, 2020, 84: 101977

[6] CohenEEW, BellRB, BifulcoCB, et al.. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer, 2019, 7(1): 184

[7] BrahmerJR, TykodiSS, ChowLQM, et al.. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med, 2012, 366(26): 2455-2465

[8] CercekA, LumishM, SinopoliJ, et al.. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med, 2022, 386(25): 2363-2376

[9] FordePM, ChaftJE, SmithKN, et al.. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med, 2018, 378(21): 1976-1986

[10] ChenS, CrabillGA, PritchardTS, et al.. Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer, 2019, 7(1): 305

[11] TopalianSL, TaubeJM, PardollDM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science, 2020, 367(6477): eaax0182

[12] RowshanravanB, HallidayN, SansomDM. CTLA-4: a moving target in immunotherapy. Blood, 2018, 131(1): 58-67

[13] BoutrosC, TarhiniA, RoutierE, et al.. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol, 2016, 13(8): 473-486

[14] SchoenfeldJD, HannaGJ, JoVY, et al.. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol, 2020, 6(10): 1563-1570

[15] KleefR, BacherV, NagyR, et al.. Complete Remission of Vocal Cord Cancer Treated With Low-Dose Ipilimumab Plus Nivolumab Combined With Interleukin-2 and Hyperthermia. Cureus, 2021, 13(4): e14500

[16] WolchokJD, KlugerH, CallahanMK, et al.. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med, 2013, 369(2): 122-133

[17] RibasA, WolchokJD. Cancer immunotherapy using checkpoint blockade. Science, 2018, 359(6382): 1350-1355

[18] ChangALS, KimJ, LucianoR, et al.. A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor. JAMA Dermatol, 2016, 152(1): 106-108

[19] SeiwertTY, BurtnessB, MehraR, et al.. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol, 2016, 17(7): 956-965

[20] HarringtonKJ, FerrisRL, BlumenscheinG, et al.. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol, 2017, 18(8): 1104-1115

[21] FerrisRL, BlumenscheinG, FayetteJ, et al.. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med, 2016, 375(19): 1856-1867

[22] BurtnessB, HarringtonKJ, GreilR, et al.. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, 2019, 394(10212): 1915-1928

[23] LeidnerR, CrittendenM, YoungK, et al.. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. J Immunother Cancer, 2021, 9(5): e002485

[24] UppaluriR, CampbellKM, EgloffAM, et al.. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clin Cancer Res, 2020, 26(19): 5140-5152

[25] WoodsRSR, NaudeA, O’sullivanJB, et al.. Management of Temporal Bone Malignancy in Ireland. J Neurol Surg B Skull Base, 2020, 81(6): 680-685

[26] MoritaS, MizumachiT, NakamaruY, et al.. Comparison of the University of Pittsburgh staging system and the eighth edition of the American Joint Committee on Cancer TNM classification for the prognostic evaluation of external auditory canal cancer. Int J Clin Oncol, 2018, 23(6): 1029-1037

[27] ShinomiyaH, UeharaN, TeshimaM, et al.. Clinical management for T1 and T2 external auditory canal cancer. Auris Nasus Larynx, 2019, 46(5): 785-789

[28] SeligmanKL, SunDQ, Ten EyckPP, et al.. Temporal bone carcinoma: Treatment patterns and survival. Laryngoscope, 2020, 130(1): E11-E20

[29] MehtaGU, MuellemanTJ, BrackmannDE, et al.. Temporal bone resection for lateral skull-base malignancies. J Neurooncol, 2020, 150(3): 437-444

[30] MuraiT, KamataSE, SatoK, et al.. Hypofractionated Stereotactic Radiotherapy for Auditory Canal or Middle Ear Cancer. Cancer Control, 2016, 23(3): 311-316

[31] ChoiJ, KimSH, KohYW, et al.. Tumor Stage-Related Role of Radiotherapy in Patients with an External Auditory Canal and Middle Ear Carcinoma. Cancer Res Treat, 2017, 49(1): 178-184

[32] GandhiAK, RoyS, BiswasA, et al.. Treatment of squamous cell carcinoma of external auditory canal: A tertiary cancer centre experience. Auris Nasus Larynx, 2016, 43(1): 45-49

[33] WangHM, LinCY, HsiehCH, et al.. Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer. J Formos Med Assoc, 2017, 116(3): 185-192

[34] MiyauchiS, KimSS, PangJ, et al.. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. Clin Cancer Res, 2019, 25(14): 4211-4223

[35] MoritaS, HommaA, NakamaruY, et al.. The Outcomes of Surgery and Chemoradiotherapy for Temporal Bone Cancer. Otol Neurotol, 2016, 37(8): 1174-1182

[36] TakenakaY, ChoH, NakaharaS, et al.. Chemoradiation therapy for squamous cell carcinoma of the external auditory canal: A meta-analysis. Head Neck, 2015, 37(7): 1073-1080

[37] ShinomiyaH, HasegawaS, YamashitaD, et al.. Concomitant chemoradiotherapy for advanced squamous cell carcinoma of the temporal bone. Head Neck, 2016, 38(Suppl 1): E949-E953

[38] KitaniY, KubotaA, FurukawaM, et al.. Primary definitive radiotherapy with or without chemotherapy for squamous cell carcinoma of the temporal bone. Eur Arch Otorhinolaryngol, 2016, 273(5): 1293-1298

[39] ConcuR, CordeiroMNDS. Cetuximab and the Head and Neck Squamous Cell Cancer. Curr Top Med Chem, 2018, 18(3): 192-198

[40] CramerJD, BurtnessB, LeQT, et al.. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol, 2019, 16(11): 669-683

[41] BonnerJ A, HarariP M, GiraltJ, et al.. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med, 2006, 354(6): 567-578

[42] VermorkenJB, MesiaR, RiveraF, et al.. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med, 2008, 359(11): 1116-1127

[43] MoritaS, NakamaruY, HommaA, et al.. Expression of p53, p16, cyclin D1, epidermal growth factor receptor and Notch1 in patients with temporal bone squamous cell carcinoma. Int J Clin Oncol, 2017, 22(1): 181-189

[44] EbisumotoK, OkamiK, HamadaM, et al.. Cetuximab with radiotherapy as an alternative treatment for advanced squamous cell carcinoma of the temporal bone. Auris Nasus Larynx, 2018, 45(3): 637-639

[45] RavulapatiS, LeungC, PoddarN, et al.. Immunotherapy in Squamous Cell Skin Carcinoma: A Game Changer?. Am J Med, 2017, 130(5): e207-e208

[46] DegacheE, CrochetJ, SimonN, et al.. Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol, 2018, 32(7): e257-e258

[47] ChenA, AliN, BoasbergP, et al.. Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab. J Clin Med, 2018, 7(1): 10